DE59006080D1 - Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum. - Google Patents

Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.

Info

Publication number: DE59006080D1
Authority: DE; Germany
Prior art keywords: hiv; infections; protection against; immunotherapeutic; vaccine
Prior art date: 1989-10-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Revoked

Application number

DE59006080T

Other languages

English (en)

Inventor

Ursula Dietrich

Michalina Adamski

Briesen Hagen Von

Herbert Kuehnel

Helga Ruebsamen-Waigmann

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Chemotherapeutisches Forschungsinstitut Georg Speyer Haus

Original Assignee

Chemotherapeutisches Forschungsinstitut Georg Speyer Haus

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-10-14

Filing date

1990-10-12

Publication date

1994-07-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6391493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE59006080(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-10-12 Application filed by Chemotherapeutisches Forschungsinstitut Georg Speyer Haus filed Critical Chemotherapeutisches Forschungsinstitut Georg Speyer Haus

1990-10-12 Priority to DE59006080T priority Critical patent/DE59006080D1/de

1994-07-14 Application granted granted Critical

1994-07-14 Publication of DE59006080D1 publication Critical patent/DE59006080D1/de

2010-10-13 Anticipated expiration legal-status Critical

Status Revoked legal-status Critical Current

Links

238000000034 method Methods 0.000 title abstract 4
229960005486 vaccine Drugs 0.000 title abstract 4
230000001024 immunotherapeutic effect Effects 0.000 title abstract 2
208000015181 infectious disease Diseases 0.000 title abstract 2
208000031886 HIV Infections Diseases 0.000 abstract 6
241000713340 Human immunodeficiency virus 2 Species 0.000 abstract 2
241000700605 Viruses Species 0.000 abstract 1
238000010171 animal model Methods 0.000 abstract 1
239000000032 diagnostic agent Substances 0.000 abstract 1
229940039227 diagnostic agent Drugs 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000002955 immunomodulating agent Substances 0.000 abstract 1
238000009169 immunotherapy Methods 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test

DE59006080T 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum. Revoked DE59006080D1 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
DE59006080T DE59006080D1 (de)	1989-10-14	1990-10-12	Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE3934366A DE3934366A1 (de)	1989-10-14	1989-10-14	Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
DE59006080T DE59006080D1 (de)	1989-10-14	1990-10-12	Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.
PCT/EP1990/001729 WO1991005567A1 (de)	1989-10-14	1990-10-12	Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum

Publications (1)

Publication Number	Publication Date
DE59006080D1 true DE59006080D1 (de)	1994-07-14

Family

ID=6391493

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE3934366A Granted DE3934366A1 (de)	1989-10-14	1989-10-14	Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
DE59006080T Revoked DE59006080D1 (de)	1989-10-14	1990-10-12	Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE3934366A Granted DE3934366A1 (de)	1989-10-14	1989-10-14	Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum

Country Status (8)

Country	Link
US (1)	US5861243A (de)
EP (1)	EP0495896B1 (de)
JP (1)	JP3152433B2 (de)
AT (1)	ATE106748T1 (de)
DE (2)	DE3934366A1 (de)
DK (1)	DK0495896T3 (de)
ES (1)	ES2055922T3 (de)
WO (1)	WO1991005567A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2047073A1 (en) *	1990-07-19	1992-01-20	William J. Leanza	Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties
US5274122A (en) *	1992-10-15	1993-12-28	Merck & Co., Inc.	Acidic derivatives of homocysteine thiolactone
US6399294B1 (en) *	1994-10-20	2002-06-04	Institut Pasteur	Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens
US6124262A (en) *	1995-03-17	2000-09-26	The Regents Of The University Of California	Compositions and methods for reducing adhesiveness of defective red blood cells
US6426412B1 (en) *	1995-12-20	2002-07-30	Subsidiary No. 3, Inc.	Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
WO1998041657A1 (en) *	1997-03-20	1998-09-24	Affymetrix, Inc.	Iterative resequencing
US5891994A (en) *	1997-07-11	1999-04-06	Thymon L.L.C.	Methods and compositions for impairing multiplication of HIV-1
WO2000029561A2 (en)	1999-03-29	2000-05-25	Statens Serum Institut	Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
KR100863367B1 (ko) *	1999-05-13	2008-10-13	와이어쓰 홀딩스 코포레이션	보조제 배합 제형물
BR0016510A (pt) *	1999-12-23	2002-08-27	Medical Res Council	Aperfeçoamentos em ou relacionados as respostas imunes ao hiv
US6399067B1 (en) *	2000-04-28	2002-06-04	Thymon L.L.C.	Methods and compositions for impairing multiplication of HIV-1
JP2004523483A (ja) *	2000-11-10	2004-08-05	ワイス・ホールデイングス・コーポレーシヨン	アジュバントの組合せ製剤
US8076060B2 (en) *	2003-08-04	2011-12-13	Emil William Chynn	Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
EP1851247A2 (de)	2005-02-15	2007-11-07	Thymon L.L.C.	Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
US20100275278A1 (en) *	2006-02-03	2010-10-28	Karp Nelson M	Animal model for hiv induced disease
CA2735724C (en)	2008-06-19	2018-07-24	Variation Biotechnologies Inc.	Compositions and methods for treating influenza
US9907746B2 (en)	2009-07-06	2018-03-06	Variation Biotechnologies, Inc.	Methods for preparing vesicles and formulations produced therefrom
MX2012000372A (es)	2009-07-06	2012-02-28	Variation Biotechnologies Inc	Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
AU2011276223C1 (en)	2010-07-06	2016-05-12	Variation Biotechnologies, Inc.	Compositions and methods for treating influenza
CA2862864C (en)	2011-01-13	2018-12-11	Variation Biotechnologies Inc.	Compositions and methods for treating viral infections
SI2691530T1 (en)	2011-06-10	2018-08-31	Oregon Health & Science University	CMV glycoproteins and recombinant vectors
US20140356399A1 (en)	2012-01-12	2014-12-04	Variation Biotechnologies, Inc.	Compositions and methods for treating viral infections
EP4008354A1 (de)	2012-01-27	2022-06-08	Variation Biotechnologies Inc.	Verfahren und zusammensetzungen für therapeutika
CN115124628B (zh) *	2021-03-27	2023-03-31	中国科学院昆明植物研究所	一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2104556T3 (es) *	1987-01-16	1997-10-16	Pasteur Institut	Peptidos que tienen propiedades inmunologicas de hiv-2.
ES2194029T5 (es) *	1988-06-14	2016-10-26	Qiagen Gmbh	Variantes del virus HIV-2

1989
- 1989-10-14 DE DE3934366A patent/DE3934366A1/de active Granted
1990
- 1990-10-12 DE DE59006080T patent/DE59006080D1/de not_active Revoked
- 1990-10-12 JP JP51473190A patent/JP3152433B2/ja not_active Expired - Fee Related
- 1990-10-12 ES ES90915992T patent/ES2055922T3/es not_active Expired - Lifetime
- 1990-10-12 AT AT90915992T patent/ATE106748T1/de not_active IP Right Cessation
- 1990-10-12 DK DK90915992.3T patent/DK0495896T3/da active
- 1990-10-12 EP EP90915992A patent/EP0495896B1/de not_active Revoked
- 1990-10-12 WO PCT/EP1990/001729 patent/WO1991005567A1/de not_active Application Discontinuation
1997
- 1997-11-12 US US08/968,689 patent/US5861243A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO1991005567A1 (de)	1991-05-02
ES2055922T3 (es)	1994-09-01
DK0495896T3 (da)	1994-10-10
EP0495896B1 (de)	1994-06-08
JPH05505389A (ja)	1993-08-12
DE3934366A1 (de)	1991-04-18
DE3934366C2 (de)	1991-11-07
JP3152433B2 (ja)	2001-04-03
US5861243A (en)	1999-01-19
EP0495896A1 (de)	1992-07-29
ATE106748T1 (de)	1994-06-15

Similar Documents

Publication	Publication Date	Title
DE59006080D1 (de)	1994-07-14	Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.
MX9203458A (es)	1992-09-01	Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
ATE172642T1 (de)	1998-11-15	Impfstoffe und verfahren zu ihrer herstellung
DK0440777T3 (da)	1997-04-21	Neurotrofisk faktor stammende fra hjernen
ATE135747T1 (de)	1996-04-15	Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
DE3784907T2 (de)	1993-06-24	Oligosaccharide, immunogene und impstoffe und verfahren zur herstellung dieser oligosaccharide, immunogene und impstoffe.
GR3022248T3 (en)	1997-04-30	Oligonucleotide sequences for amplification of type HIV-2 and SIV retroviruses genomes and their application to in-vitro diagnostic of infections caused by these viruses
ATE82985T1 (de)	1992-12-15	Strukturelles phosphoprotein (pp 150) des menschlichen cytomegalovirus, seine herstellung und verwendung.
ES469937A1 (es)	1978-12-16	Procedimiento para preparar una nueva cepa del virus de la rabia.
SE7706425L (sv)	1977-12-04	Forfarande for framstellning av polyribonukleotider med aktivitet vid alstrandet av leukocyter och blodplettar
ATE335821T1 (de)	2006-09-15	Verfahren und zusammensetzungen zur diagnose von rochalimaea henselae und rochalimaea quintana infektion
NZ222766A (en)	1990-09-26	Aids virus antigens: env/gag polypeptides: production by genetic engineering techniques: vaccines, and methods of diagnostic testing
FR2600079B1 (fr)	1989-10-20	Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
GR3018208T3 (en)	1996-02-29	Outer membrane protein p1 and peptides of haemophilus influenzae type b.
HUT54412A (en)	1991-02-28	Process for producing retrovirus proteaze, reverze transkriptaze and endonucleaze enzymes
DE2966648D1 (en)	1984-03-15	Vaccine against diseases caused by reo viruses, combined vaccine with newcastle disease virus, process for preparing them and reo virus strain used for their preparation
TH6220EX (th)	1989-07-03	ไวรัสแอนทิเจนวิธีการเตรียมและการใช้ในการวินิจฉัยและในการรักษา(วัคซีน)
TH9629EX (th)	1991-10-01	โพรเทเอส, รีเวอร์ส แทรนส์คริพเทส และเอนโดนิวคลี เอสของ ของเรโทรไวรัส และวิธีการสำหรับผลิตเอนไซม์เหล่า นี้
TH58373B (th)	2003-09-17	อิมมูโนเจนที่ถูกเพิ่มกำลัง สำหรับวัคซีนที่ไม่ถูกกระตุ้นเพื่อต่อสู้กับโรคที่เป็นการติดเชื้อที่มีสาเหตุมาจากกลุ่มของเจเปเนส เอนซีฟาลิทีสไวรัส และวิธีการเพื่อผลิตสิ่งนั้น
RU92003985A (ru)	1997-02-10	Способ получения биоларвицидных препаратов
Lefèvre et al.	1989	Improvement of the rinderpest vaccine thermostability: End of year 1 and 2 report
TH23870A (th)	1997-03-05	วัคซีนและวิธีสำหรับการเตรียม
WO1998046742A3 (de)	1999-01-21	Dictyocaulus viviparus antigen zur diagnose des lungenwurmbefalls und zur vakzinierung

Legal Events

Date	Code	Title	Description
1995-06-01	8363	Opposition against the patent
1999-12-16	8331	Complete revocation